Analysts See $-0.15 EPS for Anixa Biosciences, Inc. (ANIX)

Analysts expect Anixa Biosciences, Inc. (NASDAQ:ANIX) to report $-0.15 EPS on December, 7.After having $-0.30 EPS previously, Anixa Biosciences, Inc.’s analysts see -50.00 % EPS growth. The stock decreased 2.00% or $0.08 during the last trading session, reaching $3.92. About 54,465 shares traded. Anixa Biosciences, Inc. (NASDAQ:ANIX) has 0.00% since December 2, 2017 and is . It has underperformed by 15.62% the S&P500.

Anixa Biosciences, Inc. develops, acquires, and licenses emerging technologies in the areas of biotechnology. The company has market cap of $73.29 million. The firm develops Cchek, a platform for non-invasive blood tests for the early detection of various cancers, including breast, lung, colon, melanoma, ovarian, liver, thyroid, pancreatic, appendiceal, uterine, osteosarcoma, leiomyosarcoma, liposarcoma, vulvar, and prostate cancer. It currently has negative earnings. It also develops immuno-therapy drugs for the treatment of cancer.

More notable recent Anixa Biosciences, Inc. (NASDAQ:ANIX) news were published by: Streetinsider.com which released: “Anixa Biosciences (ANIX) Files Pre-Submission, Requests Meeting with FDA Regarding Cchek – StreetInsider.com” on October 15, 2018, also Prnewswire.com with their article: “ITUS Corporation Changing Company Name to Anixa Biosciences and Stock Ticker Symbol to ANIX – PR Newswire” published on September 28, 2018, Seekingalpha.com published: “Finding Alpha In Event-Driven Patent-Litigation Investments – Seeking Alpha” on February 20, 2014. More interesting news about Anixa Biosciences, Inc. (NASDAQ:ANIX) were released by: Stockhouse.com and their article: “Anixa Biosciences to Present at SITC Annual Meeting – Stockhouse” published on October 29, 2018 as well as Streetinsider.com‘s news article titled: “B.Riley/FBR Starts Anixa Biosciences (ANIX) at Buy – StreetInsider.com” with publication date: October 03, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.